CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis Relationship to vasoactive intestinal polypeptide by Ruff, Michael R. et al.
Volume 211, number 1, 17-22 FEB 04365 January 1987 
CD4 receptor binding peptides that block HIV infectivity 
cause human monocyte chemotaxis 
Relationship to vasoactive intestinal polypeptide 
Michael R. Ruffr, Brian M. Martin, Edward I. Ginns, William L. Farrar+ and Candace B. Pert 
*Laboratory of Microbiology and Immunology, National Institute of Dental Research, NIH, Clinical Neuroscience Branch, 
National Institute of Mental Health, ADAMHA. Bethesda, MD 20892 and +National Cancer Institute, NIH. Frederick 
Cancer Research Facility, Frederick, MD 21701-1240, USA 
Received 14 November 1986; revised version received 23 November 1986 
The octapeptide Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (peptide T) and two structural analogs are potent agon- 
ists of human monocyte chemotaxis, evincing identical rank potency orders as was previously shown for 
their inhibition of human immunodeficiency virus (HIV) envelope binding and T ceil infectivity. Chemotac- 
tic activity could be inhibited by anti-CD4 monoclonal antibodies (Mabs), but not other mononuclear cell 
Mabs. The core peptide required for chemotactic activity is a pentapeptide related to the sequence Thr-Thr- 
Asn-Tyr-Thr. Homologous pentapeptides, identified by computer search, were detected in several other 
non-HIV-related viruses as well as the neuropeptide vasoactive intestinal polypeptide (VIP). The CD4 mole- 
cule, therefore, appears to be a recognition molecule for a small signal peptide ligand whose active sequence 
is a homolog of peptide T [C8] and which may be the neuropeptide VIP. 
Receptor-binding peptide; Receptor; Chemotaxis; Human immunodeficiency virus 
1. INTRODUCTION 
Recent reports indicate that viruses may utilize 
unique and specific cell surface recognition 
molecules as their initial attachment sites. For ex- 
ample, vaccinia binds to the epidermal growth fac- 
tor (EGF) [ 11, rabies the acetylcholine receptor [2], 
Epstein Barr (EB) the complement receptor [3], 
and rheo the fl-adrenergic receptor [4]. The human 
immunodeficiency virus (HIV), the etiologic agent 
of AIDS, has been shown to bind to a surface 
molecule known as CD4 (or T4), present on T lym- 
phocytes, macrophages and other cells [5,6]. 
Binding to specific surface receptors forms a basis 
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for viral tropism to particular tissues and cells, and 
plays an important role in viral pathogenesis. We 
have recently identified the subregion of the HIV 
external glycoprotein molecule, gp120, responsible 
for binding to brain membrane and human T cells. 
We have also demonstrated that de novo synthe- 
sized low-M, peptides in the nanomolar range are 
capable of inhibiting gp120 binding and preventing 
human T cell infectivity [7]. 
Utilizing a sensitive in vitro human monocyte 
chemotaxis bioassay, we now describe potent 
picomolar chemotactic activity for peptides 
previously shown to inhibit HIV binding and infec- 
tivity. We have found that several other viruses, 
not obviously related to HIV, have amino acid se- 
quences analogous to these peptides. Vasoactive 
intestinal polypeptide (VIP) also contains a similar 
peptide sequence within its structure. Peptides with 
these sequences have been synthesized and are po- 
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tent chemoattractants. Our results suggest hat the by HPLC and characterized by amino acid analysis 
CD4 molecule could function as a recognition and sequencing using an ABI 470A gas-phase se- 
molecule for a small signal peptide. quencer with a 120A on-line HPLC. 
2. MATERIALS AND METHODS 2.3. Antibodies 
2.1. Monocyte chemotaxis 
Neuropeptide receptor-mediated chemotaxis 
was performed as described [8,9]. Briefly, 
mononuclear cells were isolated from heparinized 
blood of normal human volunteers by sedimenta- 
tion over Ficoll-Paque (Pharmacia). Migration 
was studied utilizing blind-well microchemotaxis 
chambers in which the upper and lower compart- 
ments were separated by a 5 PM pore sized 
polycarbonate membrane. Cells (5.5 x 104) in 
RPM1 media with 1% bovine albumin were placed 
in upper wells and peptide attractants in the lower 
wells. At the end of a 90 min incubation at 37°C 
monocyte migration was assessed by fixing, stain- 
ing and counting the cells adherent to the distal 
membrane. Three triplicate fields were counted 
utilizing an optical image analyzer. Data are 
presented as a stimulation index, the ratio of 
migrating cells in the test compared to buffer-alone 
wells. Migration in the presence of buffer alone 
was 20-50 cells/field in these experiments. Peak 
response migration for fMet-Leu-Phe (FMLP) oc- 
curred at 10m8 M and was 220-280 cells/field in 
these experiments (stimulation index 9.2-l 1.6) 
representing a percentage of migrating cells of 
5-8%, typical for this type of assay. Migration in 
this assay is chemotactic in nature since a ‘checker- 
board’ analysis [8], performed on peptide T, 
revealed migration to occur primarily in response 
to a positive concentration gradient. All ex- 
periments have been repeated 3-8 times. When in- 
dicated, monoclonal antibodies (Mabs) were 
included in both upper and lower wells concurrent- 
ly with test attractants. 
Antibodies with specificity for T cell (OKT4, 
OKT8, 0KT3) or monocyte (OKMl) determinants 
were purchased from Ortho Pharmaceuticals. 
3. RESULTS 
2.2. Peptides 
Peptides were synthesized by the Merrifield 
solid-phase technique and purified by HPLC at 
Peninsula Laboratories (CA). Thin-layer chroma- 
tography, high-voltage lectrophoresis, amino acid 
analysis and analytical HPLC indicated the pep- 
tides employed in these studies are >95% homo- 
geneous. In the case of VIP [l-12], the peptide 
was generated by tryptic digestion of VIP, separated 
In our initial report [7] we described ‘peptide T’, 
ASTTTNYT, whose sequence is present in the 
ARV isolate of HIV [lo], as competitively in- 
hibiting HIV binding and infectivity. We have now 
examined the dose response and rank potency of 
peptide T and several analogs as agonists in an in 
vitro assay of human monocyte chemotaxis. 
Migration detected in this assay is primarily in 
response to a positive concentration gradient [8], a 
measure of chemotaxis. The results indicate that 
peptide T has potent chemotactic agonist activity 
with an EC50 of approx. 10 -I’ M (fig.1). The high 
bioactivity (maximal activity at 4 x lo-“-8 x 
lo-” M) and the biphasic dose-dependent 
response (inhibition at higher concentrations) of 
this peptide is also characteristic of other 
chemotactic neuropeptides [8]. The single amino 
acid modified analog [D-Ala’lpeptide T was slight- 
ly more active at 8 x 10-i’ M than peptide T in this 
assay, and this may be related to this latter pep- 
tide’s greater stability [7]. The carboxyl-terminal 
amino acid (e.g. amide form or DL isomer) ap- 
pears to play a significant biological role since the 
analog [D-Ala’,D-Thr’lpeptide T-NH2 shows a 
reduced biopotency (EC50 of 2 x lo-” M, with 
peak responses observed at 10m8 M). Higher con- 
centrations of this peptide were even less effective 
(not shown). The peptide TTT is chemotactically 
inert and thus provides further evidence for 
specificity of the response. The rank potency order 
for chemotaxis, [D-Ala’lpeptide T > peptide T s 
[D-Ala’,D-Thr’lpeptide T-NHz, is identical for 
both inhibition of 1251-gp120 binding and human T 
cell infectivity by the HIV virus as reported by Pert 
et al. [7], consistent with the hypothesis that 
chemotaxis is mediated by the same receptor in- 
volved in HIV binding. 
We were also interested in defining the essential 
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Fig. 1. Peptides which block HIV infection are monocyte chemoattractants. The deduced peptide T (ASTTTNYT) and 
four analogs, indicated in the figure, were tested in an assay of human monocyte chemotaxis. Means f SE of the 
chemotactic index vs peptide concentration are presented for a representative xperiment, which was repeated 5 times. 
A chemotactic index of 9.2-11.6 was observed for peak response migration of FMLP which occurred at IO-* M. 
features of the core peptide responsible for bioac- 
tivity. An analysis of the peptide T-containing 
region of the gp120 from nine HIV isolates in- 
dicated that the only homologies were pentapep- 
tides related to the sequence TTNYT [ 1 I]. We 
therefore tested this shorter analog of peptide T 
for activity in this assay. The results indicate that 
the peptide TTNYT has even greater chemotactic 
activity than peptide T itself, having an ECso of 2 
x lo-l2 M with a peak activity in the range of 1.6 
x 10-i’ M (fig.1). Further truncation of this pep- 
tide (e.g. TNYT) destroyed the chemotactic activi- 
ty (fig.3). 
Additional evidence that these peptides exert 
their effects through the CD4 molecule is shown by 
the ability of a CD4 monoclonal antibody to block 
specifically peptide T-induced chemotaxis. The 
Mab OKT4a, capable of inhibiting HIV infectivity 
of monocytes via its binding to an epitope of the 
CD4 molecule [6], was used in these studies. Both 
[D-Ala’lpeptide T- and TTNYT-induced migration 
(fig.2A) was inhibited by a low dose (0.1 pg/ml) of 
OKT4a, but chemotaxis by the irrelevant attrac- 
tant FMLP was not affected. At a concentration of 
1 .O pug/ml non-specific inhibition of FMLP migra- 
tion was also detected. Inhibition of chemotactic 
responses at high concentrations of antibody 
(fig.2) is not limited to anti-CD4 Mabs, but occurs 
with unrelated Mabs, e.g. anti-transferrin receptor 
(not shown) and, therefore, may be due to cell ag- 
gregation or other undefined post-receptor effects. 
Inhibition of peptide T-induced chemotaxis was 
only demonstrable with Mabs which were 
specifically directed to the CD4 molecule. Other 
Mabs such as OKT8, OKT3, or OKMl directed to 
other T cell or macrophage surface antigens did 
not inhibit FMLP or peptide T chemotaxis (fig.2B) 
at 0.1 pg/ml. 
A search in the Microgenie (Beckman) software 
revealed additional viral proteins containing se- 
quences related to the protypic core peptide, 
TTNYT (see legend to fig.3). In addition to pep- 
tide T [4-81 (TTNYT) and the homologs 
represented in other HIV isolates [l 11, such as the 
sequence TTSYT, several single amino acid 
substituted pentapeptide sequences were identified 
in the viruses HTLV-I (STNYT), Epstein-Barr 
(TENYT), polio (TINYT) and in the neuropeptide 
VIP (TDNYT). To assess the relevance of these se- 
quences with respect o CD4 activity, the bioactivi- 
ty of these synthesized peptides was evaluated. A 
comparison of chemotactic activity of these com- 
pounds (fig.3) shows that the peptides TTSYT, 
STNYT and TENYT were comparably active to 
peptide T [4-81 with EC50 values in the 5 x 
10-12-10-1’ M range and peak stimulation occur- 
ring at lo-” M. The analog TDNYT, comprising 
VIP [7-l 11, was also quite active, but was slightly 
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Fig.2. Mab inhibition of peptide T chemotaxis. (A) The Mab, OKT4a, with specificity for an epitope of the CD4 
molecule specifically inhibits chemotaxis by peptide T analogs [D-Ala’lpeptide T and TTNYT (both at lo-” M), but 
not the unrelated attractant FMLP, at 10m7 M. (B) Other anti-mononuclear cell Mabs do not inhibit chemotaxis. 
Percent inhibition is defined as [[l - (experimental - background)/(control - background)) x 1001. 
less potent than peptide T [4-81. The sensitivity of 
receptor-mediated events to slight structural 
changes is demonstrated by the low chemotactic 
activity of peptide TINYT. 
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4. DISCUSSION 
Structure-activity analysis indicates that human 
monocyte chemotactic activity for peptide T and 
its analogs (fig.1) follows the same rank potency 
orders previously described for inhibiting gp120 
binding to rat brain membranes and inhibition of 
HIV infection of human T cells [7]. Furthermore, 
only Mabs for the CD4 molecule, such as OKT4a 
(fig.2) or OKT4 (not shown), specifically inhibit 
peptide T or TTNYT chemotaxis, but not that of 
the irrelevant peptide FMLP. These results suggest 
Fig.3. Chemotaxis to core pentapeptides. Peptides were 
synthesized and tested as chemoattractants based on 
their relatedness to sequences present in the HIV isolates 
ARV (TTNYT); LAV and HTLV-III (TTSYT); and the 
other viruses HTLV-I (STNYT); Epstein-Barr virus 
(EBV) (TDNYT); and polio (TINYT); and the peptide 
VIP [7-111 (TDNYT). The sequences were retrieved 
with Microgenie software from Beckman Instruments 
and synthesized de novo, as described. Data are from 
three representative experiments which have been 
repeated numerous times. 
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that peptide T chemotaxis is mediated through the 
same molecular determinant hat is responsible for 
both gp120 binding and HIV infectivity and which 
is recognized by anti-CD4 Mabs. 
Other viruses such as HTLV-I and EBV, as well 
as one neuropeptide, VIP, share sequence 
homology with the prototypic core bioactive se- 
quence TTNYT, but have a single amino acid 
substitution in the second position. These peptides 
are chemotactically active (fig.3) although their 
relevance to viral function is as yet unexplored. In- 
teraction with the CD4 receptor may be necessary 
for viral replication. Alternatively, the commonali- 
ty of these sequences may indicate a relatedness 
among these virions not associated with the CD4 
receptor. 
The identification of low-M, peptides which in- 
hibit HIV infectivity and gp120 binding suggested 
that the CD4 molecule might subserve an addi- 
tional function as a recognition molecule for a 
soluble peptide ligand. Neuropeptide receptors are 
now recognized as shared components, commonly 
present on immune cells as well as nervous and en- 
docrine cells [8,9,12]. Evidence exists that several 
of the immunological defects associated with HIV 
infection, such as the immunosuppression [ 13,141, 
and polyclonal B cell activation [ 151, are not due to 
direct virus infection, but are mediated by viral 
proteins [16], most notably the large envelope 
glycoprotein, gp120. 
Our results suggest hat a previously unrecog- 
nized activity, namely interaction of the CD4 
molecule with the N-terminus of VIP may occur. 
Preliminary experiments (B.M., M.R., unpub- 
lished) indicate that the chemotactic activity of 
VIP [l-12] is indistinguishable from the peptide 
TDNYT (VIP [7-l 11) (fig.3). These results suggest 
that the endogenous ligand for the CD4 receptor 
may be the peptide VIP or a yet to be described 
close analog of the chemotactically active deduced 
‘core’ pentapeptides described in fig.3. By mimick- 
ing the action of these ‘core’ pentapeptides, viral 
proteins could exert hormone effects on CD4 
receptor bearing cells throughout the body, in- 
cluding the CNS, and thus may have a role in the 
etiology of the progressive dementia in AIDS pa- 
tients [ 171 as well as their immunological abnor- 
malities. VIP receptors have been described on 
human T cells [ 181 and localized in rodent spleen 
[19] while functionally this peptide inhibits T cell 
mitogenic responses [20]. Also, a secretory type 
diarrhea is commonly associated with the AIDS 
syndrome [21] and a significant biological action 
of VIP is stimulation of water and Cl secretion in 
the bowel [22]. Further characterization of the 
biological properties of the peptides described in 
this report could facilitate efforts to control the 
AIDS epidemic and might provide further insight 
into the pathogenetic mechanisms of other viral 
illnesses. 
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